H Lundbeck A/S (HLUYY) 34.5100 $HLUYY Don't Mak
Post# of 273318
Posted On: 09/25/2016 7:17:00 PM
H Lundbeck A/S (HLUYY) 34.5100 $HLUYY
Don't Make it Complicated, Own Drug Stocks
John Blank - Zacks Investment Research - Thu Jun 16, 6:46PM CDT
The Large Cap Pharma Industry usually looks like a solid investor niche. Place a few of your stock picking bets here.
PFE: 34.26 (+0.11), BMY: 56.48 (+0.06)
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:30AM CDT
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
PFE: 34.26 (+0.11), BMY: 56.48 (+0.06)
Why H. Lundbeck (HLUYY) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:46AM CDT
H. Lundbeck (HLUYY) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
3 Reasons Momentum Stock Investors Will Love H. Lundbeck (HLUYY)
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:33AM CDT
H. Lundbeck is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Biotie Therapies Soars on $363M Buyout Deal with Acorda
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 3:25PM CST
Acorda Therapeutics (ACOR) entered into an agreement to acquire Finnish biotech company Biotie Therapies for $363 million; the deal is expected to position Acorda as a leader in Parkinson's disease development.
BITI: 25.80 (-0.71), ACOR: 27.28 (+0.06), ANIK: 46.92 (-1.07)
Chinese Stock Market Rodeo Reopens: Global Week Ahead
John Blank - Zacks Investment Research - Mon Nov 09, 9:39AM CST
Heedless of fundamentals, Chinese retail investors and traders love to chase momentum. Upside is back in vogue.
NVO: 44.88 (-0.69), CBRL: 138.14 (-0.64), CAH: 77.66 (+0.10)
3 Reasons Why H. Lundbeck A/S (HLUYY) is a Great Momentum Stock
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 7:30AM CDT
H. Lundbeck A/S has a strong momentum score, a favorable Zacks Rank, and is seeing positive earnings estimate revisions as well
How H. Lundbeck A/S (HLUYY) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 7:56AM CDT
H. Lundbeck A/S in the Large Cap Pharma space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
Is H. Lundbeck A/S (HLUYY) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 7:36AM CDT
If you are looking for a decent pick in a strong industry, consider H. Lundbeck A/S
Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome
BusinessWire - Tue Mar 17, 9:00AM CDT
Lundbeck LLC today announced the initiation of the CLOVER I Study to investigate the use of clobazam for the treatment of children and adolescents with Dravet syndrome -- a rare and severe form of intractable epilepsy that begins in infancy.(1) Clobazam is already approved in the United States (U.S.) for seizures associated with another epilepsy syndrome.
New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy
BusinessWire - Mon Dec 08, 10:00AM CST
--Studio E Artwork on Display Across the Country to Raise Epilepsy Awareness
Five-Year Data From SABRIL(R) (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting
BusinessWire - Mon Dec 08, 10:00AM CST
A late-breaking poster presentation focused on five-year vision data from Lundbeck's SABRIL (vigabatrin) patient registry was presented at the annual meeting of the American Epilepsy Society (AES). The data set includes 6,823 patients enrolled from August 21, 2009 through August 26, 2014.(1) The U.S. Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS) due to the risk of SABRIL-induced permanent vision loss, including an ongoing patient registry.
Don't Make it Complicated, Own Drug Stocks
John Blank - Zacks Investment Research - Thu Jun 16, 6:46PM CDT
The Large Cap Pharma Industry usually looks like a solid investor niche. Place a few of your stock picking bets here.
PFE: 34.26 (+0.11), BMY: 56.48 (+0.06)
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:30AM CDT
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
PFE: 34.26 (+0.11), BMY: 56.48 (+0.06)
Why H. Lundbeck (HLUYY) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:46AM CDT
H. Lundbeck (HLUYY) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
3 Reasons Momentum Stock Investors Will Love H. Lundbeck (HLUYY)
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:33AM CDT
H. Lundbeck is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Biotie Therapies Soars on $363M Buyout Deal with Acorda
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 3:25PM CST
Acorda Therapeutics (ACOR) entered into an agreement to acquire Finnish biotech company Biotie Therapies for $363 million; the deal is expected to position Acorda as a leader in Parkinson's disease development.
BITI: 25.80 (-0.71), ACOR: 27.28 (+0.06), ANIK: 46.92 (-1.07)
Chinese Stock Market Rodeo Reopens: Global Week Ahead
John Blank - Zacks Investment Research - Mon Nov 09, 9:39AM CST
Heedless of fundamentals, Chinese retail investors and traders love to chase momentum. Upside is back in vogue.
NVO: 44.88 (-0.69), CBRL: 138.14 (-0.64), CAH: 77.66 (+0.10)
3 Reasons Why H. Lundbeck A/S (HLUYY) is a Great Momentum Stock
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 7:30AM CDT
H. Lundbeck A/S has a strong momentum score, a favorable Zacks Rank, and is seeing positive earnings estimate revisions as well
How H. Lundbeck A/S (HLUYY) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 7:56AM CDT
H. Lundbeck A/S in the Large Cap Pharma space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
Is H. Lundbeck A/S (HLUYY) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 7:36AM CDT
If you are looking for a decent pick in a strong industry, consider H. Lundbeck A/S
Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome
BusinessWire - Tue Mar 17, 9:00AM CDT
Lundbeck LLC today announced the initiation of the CLOVER I Study to investigate the use of clobazam for the treatment of children and adolescents with Dravet syndrome -- a rare and severe form of intractable epilepsy that begins in infancy.(1) Clobazam is already approved in the United States (U.S.) for seizures associated with another epilepsy syndrome.
New Study: Art Therapy May Build Self-Esteem in People Living with Epilepsy
BusinessWire - Mon Dec 08, 10:00AM CST
--Studio E Artwork on Display Across the Country to Raise Epilepsy Awareness
Five-Year Data From SABRIL(R) (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting
BusinessWire - Mon Dec 08, 10:00AM CST
A late-breaking poster presentation focused on five-year vision data from Lundbeck's SABRIL (vigabatrin) patient registry was presented at the annual meeting of the American Epilepsy Society (AES). The data set includes 6,823 patients enrolled from August 21, 2009 through August 26, 2014.(1) The U.S. Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS) due to the risk of SABRIL-induced permanent vision loss, including an ongoing patient registry.
(0)
(0)